alirinetide (GM604) / Genervon - LARVOL DELTA

GM6 attenuates Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Aβ, p-tau and inflammation. (PubMed, Alzheimers Dement) - "In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer's disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation."

Journal • Alzheimer's Disease • CNS Disorders • Immunology • Inflammation • IL1B • IL6 • TGFB1 • TNFA

[VIRTUAL] GM6 attenuates Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation. (AAIC 2021) - "In conclusion, to counter the additive adverse effect on cognition from vascular dysfunction and amyloid burden, GM6 may be a feasible approach to attenuate Alzheimer’s disease pathology through a reduction in fibrinogen levels and by regulation of Ab, p-tau and inflammation."

Alzheimer's Disease • CNS Disorders • Immunology • Inflammation • IL1B • IL6 • TGFB1 • TNFA

GAP-PD-Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease (clinicaltrials.gov) - P2a; N=6; Completed; Sponsor: Genervon Biopharmaceuticals, LLC; Recruiting ➔ Completed; Trial primary completion date: Dec 2013 ➔ Jul 2014

Trial completion • Trial primary completion date • Biosimilar • Parkinson's Disease

"It is definitely do-able. We had a petition from ALS community to FDA for GM604 approval - over 800,000 supporters 👍. https://t.co/HVz7BLwhHg" (@ArrestALSNow)

FDA event